Surface polysaccharides of Gram-negative enteric pathogens, in the form of capsule or lipopolysaccharide, are both essential virulence factors and protective antigens. The immunogenicity of these polysaccharides were enhanced by binding to carrier proteins. Sequential clinical studies in adults and in children in Vietnam, an area with a high attack rate of typhoid, showed that the capsular polysaccharide (Vi) conjugates bound to the recombinant Pseudomonas aeruginosa exoprotein A (rEPA) elicited high responses against typhi. In a Phase III trial, About 12,000 2-5 years old children injected with the conjugate vaccine showed no significant side reaction. The efficacy of Vi-rEPA was 89% after 48 months surveillance. Chidren in the pacebo group were given the conjugate vaccine 2.5 years later. A dosage study in Northern Vietnam was conducted in children 2-5 years old. Results showed there was a dose dependent antibody response. The 25 microgram dose gave the highest response, followed by 12.5 microgram dose. There is no statistical significance between the two dosages. Children injected with 5 microgram of conjugate polysaccharide,however, had significantly lower Vi antibody levels than those received higher dosages. Salmonella paratyphi A, the second most common cause of enteric fever in Southeast Asia, conjugate vaccine was found to be safe and immunogenic in adults, teenagers and then 2-4 year old children. A careful re-examination of the conjugate vaccines of S. paratyphi A indicated that the O-acetyl content of the conjugate vaccine is directly related to the immunogenicity of the conjugate vaccine. In southeast China, cases of paratyphi A has exceeded those of typhi. A phase III clinical trial is planned. Escherichia coli O157, an emerging pathogen, causes hemolytic uremic syndrome in young children. Phase 1 study of E. coli O157 O-specific polysaccharide-rEPA conjugate demonstrated safety and immunogenicity in adult volunteers. The phase II study of E. coli O157 conjugate, 55 children 2-5 years old children were recruited. Children injected once or twice showed that the vaccine was safe. Immunogenicity data showed 98% children responded with greater than 4 fold rise of anti-LPS IgG 6 months after the first injection. There was no booster response in children receiving a second dose 6 weeks after the first injection. Non-toxic shiga toxin I and II are purified from mutant E. coli O157 and will be conjugated with O-specific polysaccharide for a bivalent vaccine. The major reservoir of E.coli O157 is cattle. LPS-protein conjugate showed to be immunogenic in cattle and a challenge study showed an inversed correlation between the serum anti-LPS IgG and the level of colonization of E. coli O157 at rectal. Vibrio cholera O1 and O139 are the major sero types in cholera infections. Conjugates synthesized with capsular polysaccharide of O139 and O-specific polysaccharide of LPS of O1 elicited vibriocidal antibodies in mice. Detoxified LPS from both Inaba and Ogawa serotypes have been used as a base for conjugate vaccine. In animal study, the conjugates elicited higher antibody level than LPS alone. A chemical synthesized O-specific polysaccharide for Ogawa will be prepared and conjugated to protein carrier. The immunogenicity of cholera vaccine prepared with naturally purified or chemically synthesized O-specific polysaccharide will be compared in clinical studies. One of the most common Salmonella infection in developed country is Salmonella typhimurium. Antibiotic resistant strains have been common in disease isolates. We have compared the O-specific polysaccharide structure of the most common and antibiotic resistant strains. The O-acetyl group on the abequose is found to be a major antigenic site and an immunodominant determinant. Strains that are O-acetyl positive reacted with antibodies from O-acetyl negative strains poorly. Selection of strains for vaccine preparation will therefore rely on the epidemiology survey and bacteriology identification. Campylobacter jejuli infection is one of the most common enteric infection in the US and around the world. The most common type in US is type 2. Campylobacter is microaerophilic and fermentation in liquid mmedia has been difficult. Various media and fermentation conditions was studied and growth in liquid media were succeeded. Chemical analysis showed that the surface polysaccharide contains keto groups and does not contain colominic acid. From the size and the staining properties, we concluded that the polysaccharide is an oligo LPS. The conjugate prepared with LPS or deacetylated LPS were immunogenic and showed bactercidal activity in the presence of complement.

Project Start
Project End
Budget Start
Budget End
Support Year
21
Fiscal Year
2004
Total Cost
Indirect Cost
Name
U.S. National Inst/Child Hlth/Human Dev
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Ftacek, Peter; Nelson, Victor; Szu, Shousun C (2013) Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length. Glycoconj J 30:871-80
Moore, Sophie E; Jalil, Fehmida; Szu, Shousun Chen et al. (2008) Revaccination does not improve an observed deficit in antibody responses in Pakistani adults born of a lower birth weight. Vaccine 26:158-65
Ahmed, Amina; Li, Jianpin; Shiloach, Yossi et al. (2006) Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 193:515-21
Canh, Do Gia; Lin, Feng-ying Kimi; Thiem, Vu Dinh et al. (2004) Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 72:6586-8
Mai, Ngoc Lanh; Phan, Van Bay; Vo, Anh Ho et al. (2003) Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 349:1390-1
Lin, F Y; Ho, V A; Khiem, H B et al. (2001) The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 344:1263-9
Kossaczka, Z; Shiloach, J; Johnson, V et al. (2000) Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect Immun 68:5037-43
Konadu, E Y; Lin, F Y; Ho, V A et al. (2000) Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 68:1529-34
Kossaczka, Z; Lin, F Y; Ho, V A et al. (1999) Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 67:5806-10
Konadu, E; Donohue-Rolfe, A; Calderwood, S B et al. (1999) Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect Immun 67:6191-3